1. Pink Sheet
  2. >>Market Access

Breyanzi Becomes Fourth CAR T-Cell Therapy Reimbursed In England

 
• By Neena Brizmohun

A lower asking price from BMS and more insight into the benefits Breyanzi offers have convinced the health technology assessment institute, NICE, to reverse its rejection of the one-off treatment for large B-cell lymphoma.

3d illustration CAR T-cell attack cancer cell and healthy cells
Breyanzi is a CAR T-cell therapy for patients with large B-cell lymphoma (Shutterstock)
Key Takeaways
  • Breyanzi is now recommended for routine use via the National Health Service in England for the treatment of relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable.
  • Bristol Myers Squibb secured the reimbursement by offering an improved commercial arrangement to the NHS on the £297,000 list price, per individual treatment.
  • Also taken into account were additional benefits of the treatment that were previously not included in BMS’s economic modeling.
  • Three other CAR T-cell therapies are also reimbursed in England: Tecartus, Yescarta and Kymriah.

England’s health technology assessment institute, NICE, has reversed its rejection of the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating relapsed or refractory large B-cell lymphoma, after Bristol Myers Squibb...

Breyanzi is now recommended for routine use via the National Health Service in England for the treatment of relapsed or refractory large B-cell lymphoma after...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

More from Government Payers